KALV - KalVista Pharmaceticals GAAP EPS of -$0.98 beats by $0.11

• KalVista Pharmaceticals press release ( NASDAQ: KALV ): Q4 GAAP EPS of -$0.98 beats by $0.11 .
• Cash, cash equivalents and marketable securities were $166.2M on April 30, 2022, compared to $248.9M on April 30, 2021. The decrease in the net cash position over the fiscal year is primarily due to increased operating expenses.
• “We are pleased with the progress we have made over the last fiscal year in the development of the candidates in our oral hereditary angioedema franchise,” said Andrew Crockett, Chief Executive Officer of KalVista. “We are meeting our enrollment targets for both our current clinical trials, the sebetralstat KONFIDENT Phase 3 and KVD824 KOMPLETE Phase 2. In addition, we are making great strides in developing our next wave of investigational compounds with promising preclinical data for our oral Factor XIIa inhibitor program. The Company is also well-capitalized, with funding until at least early 2024, which we expect takes us beyond data from both of our ongoing clinical trials.”

For further details see: